+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H1 2019

  • ID: 4760063
  • Drug Pipelines
  • March 2019
  • Region: Global
  • 97 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Apogenix AG
  • BioNTech SE
  • Celldex Therapeutics Inc
  • Johnson & Johnson
  • MedImmune LLC
  • MORE
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H1 2019

Summary

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H1 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNF-receptor superfamily. This protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 6, 7 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Gastrointestinal, Genito Urinary System And Sex Hormones, Central Nervous System, Dermatology, Hormonal Disorders and Metabolic Disorders which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Kidney Transplant Rejection, Lymphoma, Ovarian Cancer, Bladder Cancer, Breast Cancer, Crohn's Disease (Regional Enteritis), Esophageal Cancer, Lupus Nephritis, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Myasthenia Gravis, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Astrocytoma, Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Central Nervous System (CNS) Tumor, Cervical Cancer, Colorectal Cancer, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Graft Versus Host Disease (GVHD), Graves Diseases, Head And Neck Cancer, Heart Transplant Rejection, Hepatic (Liver) Tumor, Hidradenitis Suppurativa, Hyperthyroidism, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liposarcoma, Liver Transplant Rejection, Malignant Mesothelioma, Membranous Glomerulonephritis, Metastatic Adenocarcinoma of The Pancreas, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Sclerosis, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Transplant Rejection, Pediatric Diffuse Intrinsic Pontine Glioma, Pemphigus, Primary Biliary Cirrhosis, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)
  • The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Apogenix AG
  • BioNTech SE
  • Celldex Therapeutics Inc
  • Johnson & Johnson
  • MedImmune LLC
  • MORE
Introduction

Report Coverage

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Overview

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Companies Involved in Therapeutics Development

AbbVie Inc

Apexigen Inc

Apogenix AG

Avacta Life Sciences Ltd

BioNTech SE

Boehringer Ingelheim GmbH

Celldex Therapeutics Inc

Denceptor Therapeutics Ltd

F. Hoffmann-La Roche Ltd

Johnson & Johnson

Kyowa Hakko Kirin Co Ltd

MedImmune LLC

Molecular Partners AG

Novartis AG

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Drug Profiles

ABBV-428 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABBV-927 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APG-1233 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-005M - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVA-023 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-655064 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Agonize CD40 and 4-1BB for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Agonize CD40 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bleselumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-1140 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNP-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FFP-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iscalimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-7107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KGYY-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPL-404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-5083 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MegaCD40L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize CD40 and Antagonize FCGR2B for B-cell Lymphoma and Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugate to Target CD40 for Pancreatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Target FAP and CD40 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selicrelumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selicrelumab + vanucizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UltraCD40L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Dormant Products

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Discontinued Products

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Product Development Milestones

Featured News & Press Releases

Jan 29, 2019: Alligator Bioscience publishes clinical phase I data for ADC-1013 in the International Journal of Cancer

Nov 09, 2018: Celldex presents promising interim data from phase 1 study of differentiated CD40 agonist CDX-1140 at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

Nov 06, 2018: Molecular Partners to present data on DARPin immuno-oncology compound FAP x CD40 at upcoming scientific conferences

Oct 11, 2018: Preclinical efficacy data of Apogenix HERA-CD40L published in Journal of Immunotherapy

May 18, 2018: Apexigen Expands Leadership Team with Appointment of Frances Rena Bahjat, Vice President, Discovery Research

Apr 20, 2018: Celldex Therapeutics presents data on CDX-1140 at AACR Annual Meeting 2018

Jan 03, 2018: Alligator Bioscience to receive USD 6 million milestone payment from Janssen coupled to the decision to initiate combination trial with ADC-1013

Nov 30, 2017: Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors

Nov 07, 2017: Results from Alligator Biosciences clinical phase I study support further clinical development of ADC-1013

Oct 31, 2017: Apexigen Announces Late-Breaking Oral Presentation for Immune Activating Antibody APX005M at the 2017 Society for Immunotherapy of Cancer Annual Meeting

Oct 25, 2017: Apexigen Announces New Collaboration with UCSF

Sep 21, 2017: Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017

Sep 20, 2017: The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy

Jul 17, 2017: Apexigen Announces First Patient Dosed in Phase 1b/2 Clinical Trial of APX005M in Combination with Opdivo (nivolumab) in Advanced Solid Tumors

May 10, 2017: Boehringer Ingelheim Phase II trial Now Enrolling Patients with the Kidney Disease Lupus Nephritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact the Publisher

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by AbbVie Inc, H1 2019

Pipeline by Apexigen Inc, H1 2019

Pipeline by Apogenix AG, H1 2019

Pipeline by Avacta Life Sciences Ltd, H1 2019

Pipeline by BioNTech SE, H1 2019

Pipeline by Boehringer Ingelheim GmbH, H1 2019

Pipeline by Celldex Therapeutics Inc, H1 2019

Pipeline by Denceptor Therapeutics Ltd, H1 2019

Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Pipeline by Johnson & Johnson, H1 2019

Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2019

Pipeline by MedImmune LLC, H1 2019

Pipeline by Molecular Partners AG, H1 2019

Pipeline by Novartis AG, H1 2019

Dormant Products, H1 2019

Discontinued Products, H1 2019

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • Apexigen Inc
  • Apogenix AG
  • Avacta Life Sciences Ltd
  • BioNTech SE
  • Boehringer Ingelheim GmbH
  • Celldex Therapeutics Inc
  • Denceptor Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co Ltd
  • MedImmune LLC
  • Molecular Partners AG
  • Novartis AG
Note: Product cover images may vary from those shown
Adroll
adroll